712 related articles for article (PubMed ID: 27589333)
1. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
[TBL] [Abstract][Full Text] [Related]
2. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
3. Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
Kratochwil C; Afshar-Oromieh A; Kopka K; Haberkorn U; Giesel FL
Semin Nucl Med; 2016 Sep; 46(5):405-18. PubMed ID: 27553466
[TBL] [Abstract][Full Text] [Related]
4. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
[TBL] [Abstract][Full Text] [Related]
5. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy.
Eiber M; Fendler WP; Rowe SP; Calais J; Hofman MS; Maurer T; Schwarzenboeck SM; Kratowchil C; Herrmann K; Giesel FL
J Nucl Med; 2017 Sep; 58(Suppl 2):67S-76S. PubMed ID: 28864615
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
Hofman MS; Hicks RJ; Maurer T; Eiber M
Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
[TBL] [Abstract][Full Text] [Related]
8. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.
Afshar-Oromieh A; Babich JW; Kratochwil C; Giesel FL; Eisenhut M; Kopka K; Haberkorn U
J Nucl Med; 2016 Oct; 57(Suppl 3):79S-89S. PubMed ID: 27694178
[TBL] [Abstract][Full Text] [Related]
9. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
10. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.
Ceci F; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482
[TBL] [Abstract][Full Text] [Related]
11. PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.
Debnath S; Zhou N; McLaughlin M; Rice S; Pillai AK; Hao G; Sun X
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163083
[TBL] [Abstract][Full Text] [Related]
12. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A
J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
14. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
15. PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy.
Wester HJ; Schottelius M
Semin Nucl Med; 2019 Jul; 49(4):302-312. PubMed ID: 31227053
[TBL] [Abstract][Full Text] [Related]
16. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
[TBL] [Abstract][Full Text] [Related]
17. The
Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
[TBL] [Abstract][Full Text] [Related]
18. Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker.
Huang SS; Wang X; Zhang Y; Doke A; DiFilippo FP; Heston WD
Prostate; 2014 May; 74(7):702-13. PubMed ID: 24615708
[TBL] [Abstract][Full Text] [Related]
19. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
Hofman MS; Iravani A
PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
[TBL] [Abstract][Full Text] [Related]
20. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.
Lapi SE; Wahnishe H; Pham D; Wu LY; Nedrow-Byers JR; Liu T; Vejdani K; VanBrocklin HF; Berkman CE; Jones EF
J Nucl Med; 2009 Dec; 50(12):2042-8. PubMed ID: 19910433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]